Home › Chronic Lymphocytic Leukemia › NCT06876662
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are: * receiving study intervention * in the short-term follow-up period, or * in the long-term follow-up period Exclusion Criteria: * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001
About the study
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
What is being tested
- Pirtobrutinib (drug)
Sponsor: Eli Lilly and Company · Participants: 279 · Started: May 20, 2025
Contact the study team
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · Phone: 1-317-615-4559
Official record on ClinicalTrials.gov — NCT06876662
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.